WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318763
CAS#: 68-35-9
Description: Sulfadiazine eliminates bacteria that cause infections by stopping the production of folate inside the bacterial cell, and is commonly used to treat urinary tract infections, and burns. In combination, sulfadiazine and pyrimethamine, can be used to treat toxoplasmosis.
Hodoodo Cat#: H318763
Name: Sulfadiazine
CAS#: 68-35-9
Chemical Formula: C10H10N4O2S
Exact Mass: 250.05
Molecular Weight: 250.276
Elemental Analysis: C, 47.99; H, 4.03; N, 22.39; O, 12.79; S, 12.81
Synonym: RP-2616; RP2616; RP 2616; Sulfadiazine; Liquadiazine; Microsulfon
IUPAC/Chemical Name: 4-amino-N-(pyrimidin-2-yl)benzenesulfonamide
InChi Key: SEEPANYCNGTZFQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
SMILES Code: O=S(NC1=NC=CC=N1)(C2=CC=C(N)C=C2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 250.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Rashaan ZM, Krijnen P, Klamer RR, Schipper IB, Dekkers OM, Breederveld RS. Nonsilver treatment vs. silver sulfadiazine in treatment of partial-thickness burn wounds in children: a systematic review and meta-analysis. Wound Repair Regen. 2014 Jul-Aug;22(4):473-82. doi: 10.1111/wrr.12196. Review. PubMed PMID: 24899251.
2: Prosdocimi M, Bevilacqua C. Impaired wound healing in diabetes: the rationale for clinical use of hyaluronic acid plus silver sulfadiazine. Minerva Med. 2012 Dec;103(6):533-9. Review. PubMed PMID: 23229372.
3: Miller AC, Rashid RM, Falzon L, Elamin EM, Zehtabchi S. Silver sulfadiazine for the treatment of partial-thickness burns and venous stasis ulcers. J Am Acad Dermatol. 2012 May;66(5):e159-65. doi: 10.1016/j.jaad.2010.06.014. Epub 2010 Aug 17. Review. PubMed PMID: 20724028.
4: Fuller FW. The side effects of silver sulfadiazine. J Burn Care Res. 2009 May-Jun;30(3):464-70. doi: 10.1097/BCR.0b013e3181a28c9b. Review. PubMed PMID: 19349889.
5: Petersen E, Schmidt DR. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options? Expert Rev Anti Infect Ther. 2003 Jun;1(1):175-82. Review. PubMed PMID: 15482110.
6: Catalano-Pons C, Bargy S, Schlecht D, Tabone MD, Deschênes G, Bensman A, Ulinski T. Sulfadiazine-induced nephrolithiasis in children. Pediatr Nephrol. 2004 Aug;19(8):928-31. Epub 2004 Jun 17. Review. PubMed PMID: 15206032.
7: Chung JY, Herbert ME. Myth: silver sulfadiazine is the best treatment for minor burns. West J Med. 2001 Sep;175(3):205-6. Review. PubMed PMID: 11527855; PubMed Central PMCID: PMC1071544.
8: Becker K, Jablonowski H, Häussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore). 1996 Jul;75(4):185-94. Review. PubMed PMID: 8699959.
9: Frenia ML, Schauben P. Use of silver sulfadiazine in Stevens-Johnson syndrome. Ann Pharmacother. 1994 Jun;28(6):736-7. Review. PubMed PMID: 7919562.
10: Fuller FW, Parrish M, Nance FC. A review of the dosimetry of 1% silver sulfadiazine cream in burn wound treatment. J Burn Care Rehabil. 1994 May-Jun;15(3):213-23. Review. PubMed PMID: 8056810.
11: Kronawitter U, Jakob K, Zoller WG, Rauh G, Goebel FD. [Acute kidney failure caused by sulfadiazine stones. A complication of the therapy of toxoplasmosis in AIDS]. Dtsch Med Wochenschr. 1993 Nov 19;118(46):1683-6. Review. German. PubMed PMID: 8243240.
12: Simon DI, Brosius FC 3rd, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990 Nov;150(11):2379-84. Review. PubMed PMID: 2241449.
13: Bocchiotti G, Robotti E. [The use of a topical antibacterial agent (silver sulfadiazine) on soft-tissue wounds]. Minerva Chir. 1990 May 15;45(9):677-81. Review. Italian. PubMed PMID: 2202932.
14: Gilman TM, Boylen CT, Sattler FR. Pyrimethamine-sulfadiazine for treating Pneumocystis carinii pneumonia and toxoplasmosis in AIDS. Clin Pharm. 1989 Feb;8(2):84, 87. Review. PubMed PMID: 2645082.
15: Gambaro MG, Genoni P, Berra D. [A sulfadiazine-tetroxoprim combination (co-tetroxazine) in the treatment of the acute exacerbation of chronic bronchitis]. Minerva Med. 1988 Jul;79(7):563-8. Review. Italian. PubMed PMID: 3043259.
16: Hoffmann S. Silver sulfadiazine: an antibacterial agent for topical use in burns. A review of the literature. Scand J Plast Reconstr Surg. 1984;18(1):119-26. Review. PubMed PMID: 6377481.